Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.54 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.54 |
| ▸ | PDE5A | O76074 | 10/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20278520 | 0.92 | ADORA3 (0.66) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL173886 | 0.91 | ADORA3 (0.64) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL431127 | 0.90 | ADORA3 (0.65) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL430664 | 0.90 | KCNH2 (0.65) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL255860 | 0.90 | KCNH2 (0.64) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Hydrochloric Acid SCHEMBL427311 | 0.90 | ADORA3 (0.63) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL431126 | 0.89 | ADORA3 (0.62) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL245457 | 0.88 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29379983 | 0.88 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29357210 | 0.88 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| EP-3325013-B1 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND/OR AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-10736896-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-02 | — | — | US | disclosed |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | ADVERIO PHARMA GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-9993476-B2 | Substituted 5-flouro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20130237551-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8420656-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420656-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736896-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | KCNH2 128/4885ADORA3 1633/4885GUCY1A1 1337/4885 |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | PDE5A, GUCY1A1, PDE2A | KCNH2 1624/4885ADORA3 124/4885GUCY1A1 2/4885 |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | KCNH2 128/4885ADORA3 1633/4885GUCY1A1 1337/4885 |
| US-20130237551-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | KCNH2 128/4885ADORA3 1633/4885GUCY1A1 1337/4885 |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | KCNH2 3014/4885ADORA3 2019/4885GUCY1A1 8/4885 |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | PDE5A, PDE3A, PDE2A | KCNH2 2826/4885ADORA3 3197/4885GUCY1A1 6/4885 |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | KCNH2 3014/4885ADORA3 2019/4885GUCY1A1 8/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | KCNH2 128/4885ADORA3 1633/4885GUCY1A1 1337/4885 |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | KCNH2 3014/4885ADORA3 2019/4885GUCY1A1 8/4885 |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | KCNH2 128/4885ADORA3 1633/4885GUCY1A1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.